Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB6411 in Recurrent or Metastatic Esophageal Cancer
NCT07367516Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TQB6411 in esophageal cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2026; status: recruiting.
02
Drugs
TQB6411
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT07367516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367516.